BioCentury
ARTICLE | Clinical News

Faslodex fulvestrant: Phase III; marketed to treat hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following

August 11, 2003 7:00 AM UTC

AZN began an international, double-blind Phase III trial in 660 women with advanced breast cancer whose disease has recurred or progressed on treatment with a nonsteroidal aromatase inhibitor (NSAI)....